Journal of Pioneering Medical Science · Apr 5, 2026

Beyond Glycemic Control: Exploring the Prospective of Exendin-4 Clinical Utility as a Disease-Modifying Agent in Alzheimer's Disease; Preclinical and Clinical Evidence

By Hassan AES, Fahmy EK, Esmaeel SE et al.

Amyloid-beta (Aβ) plaques, neurofibrillary tangles of hyperphosphorylated tau, and persistent neuroinflammation are the hallmarks of Alzheimer's disease (AD), a progressive neurodegenerative illness that frequently manifests symptoms of cerebral insulin resistance. The possible neuroprotective properties of Exendin-4 (Ex-4), a long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA) currently licensed for type 2 diabetes mellitus (T2DM), have attracted a lot of attention. Ex-4 effectively reduces (Aβ) buildup, mitigates tau hyperphosphorylation, and suppresses neuroinflammation and oxidative stress through the GLP-1 receptor (GLP-1R) pathway, as preclinical studies show. Although these data point to Ex-4 as a potentially effective disease-modifying drug, human clinical trials have so far shown conflicting findings about the cognitive and clinical effects of Ex-4 in moderate cognitive impairment (MCI) and early AD. The present body of evidence is summarized in this review, which also examines the known mechanisms of Ex-4 neuroprotection, examines the results of finished clinical studies, and talks about the direction of its clinical use in Alzheimer's disease.

doi.org/10.47310/jpms2026150307Open accessInterventions

AgingResearch.News